Replies to post #227705 on Biotech Values

[DewDiligence]

Re: Vascepa vs Inclisiran NPV

Well, I wouldn’t have posed the question if I thought the answer were obvious, so it follows that I respectfully disagree with your conclusion.

I suspect that you are applying a substantially larger CVOT-failure discount to Inclisiran than I am.